SCHEMBL3020144

SCHEMBL3020144

COc1ccc(OC)c(Cc2csc(N3CCC(S(=O)(=O)c4cc(Cl)cc(Cl)c4)CC3)n2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CMA1 P23946 1/20 0.37
MAPT P10636 7/20 0.37
LMNA P02545 3/20 0.37
RECQL P46063 2/20 0.37
POLB P06746 1/20 0.37
ADRB2 P07550 1/20 0.37
TSHR P16473 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
TP53 P04637 2/20 0.36
ALDH1A1 P00352 4/20 0.35
HSD17B10 Q99714 2/20 0.35
HPGD P15428 1/20 0.35
L3MBTL1 Q9Y468 3/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
GAA P10253 1/20 0.35
MAPK1 P28482 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3001553 0.95 CMA1 (0.41) RAB9ASMN1; SMN2CMA1MAPTLMNA
SCHEMBL3019030 0.93 KDM1A (0.39) RAB9ASMN1; SMN2MAPTLMNARECQL
SCHEMBL3011725 0.93 MAPT (0.38) RAB9ASMN1; SMN2MAPTLMNARECQL
SCHEMBL2998369 0.91 RAB9A (0.37) RAB9ASMN1; SMN2CMA1MAPTLMNA
SCHEMBL3002108 0.90 ALDH1A1 (0.39) RAB9ASMN1; SMN2MAPTLMNARECQL
SCHEMBL3017438 0.90 KDM4E (0.43) RAB9ASMN1; SMN2MAPTLMNARECQL
SCHEMBL3022378 0.90 MAPT (0.39) RAB9ASMN1; SMN2CMA1MAPTLMNA
SCHEMBL3014518 0.90 MAPT (0.39) RAB9ASMN1; SMN2MAPTLMNARECQL
SCHEMBL3011644 0.89 MAPT (0.36) CMA1MAPTALDH1A1HSD17B10L3MBTL1
SCHEMBL3017937 0.89 TP53 (0.39) RAB9ASMN1; SMN2MAPTLMNARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA RAB9A 2943/4885SMN1; SMN2 1/4885CMA1 1626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.